Captopril-related (and -induced?) asthma.
Captopril-related (and -induced?) asthma.
复制标题
卡托普利相关（和诱发？）哮喘。
DOI：
10.1164/ajrccm/136.4.999
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
V. Popa
中科院分区：
文献类型：
--
作者：
V. Popa
一名51岁的非吸烟男性患者，既往无任何过敏、哮喘、花粉热或荨麻疹病史，在纳多洛尔和噻嗪类药物治疗高血压的同时加入卡托普利后，发生哮喘发作。纳多洛尔和卡托普利的双盲试验分别使FEV1降低3%和12%。这证实了卡托普利相关哮喘的病史。由于血管紧张素转换酶似乎在支气管炎介质的产生和代谢中起作用，这种罕见的药物诱导的哮喘对临床医生和气道药理学家都很重要。
A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure. A double-blind challenge with nadolol and captopril decreased FEV1 by 3 and 12%, respectively. This confirmed the history of captopril-related asthma. As angiotensin-converting enzyme seems to play a role in the genesis and metabolism of bronchomotor mediators, this rare form of drug-induced asthma is important for both clinicians and airways pharmacologists.